![Barbara Fox](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barbara S.
Fox was the founder of Avaxia Biologics, Inc. (founded in 2005) and Recovery Pharmaceuticals, Inc. (founded in 1998), where she held the titles of Chief Executive Officer & Director and President & Chief Scientific Officer, respectively.
Currently, she is the Chief Executive Officer at Rheos Medicines, Inc. (since 2019) and an Advisor at The Engine Accelerator, Inc. (current job).
Her former positions include Chief Executive Officer & Director at Tilos Therapeutics, Inc., Vice President-Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor at University of Maryland Medical System Corp.
Dr. Fox holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Bryn Mawr College.
| Bedrijven | Functie | Begin |
|---|---|---|
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease | Algemeen Directeur | 21-10-2019 |
The Engine Accelerator, Inc.
 The Engine Accelerator, Inc. Investment ManagersFinance Engine Ventures seeks investment opportunities in companies located in the United States. The firm targets companies operating across a broad range of sectors and industries. It provides financing for early stage transactions. | Consultant / Adviseur | - |
| Bedrijven | Functie | Einde |
|---|---|---|
Tilos Therapeutics, Inc.
 Tilos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for cancer, fibrosis and autoimmune disease | Algemeen Directeur | 21-10-2019 |
University of Maryland Medical System Corp.
 University of Maryland Medical System Corp. Hospital/Nursing ManagementHealth Services Operates hospital | Corporate Officer/Principal | - |
Recovery Pharmaceuticals, Inc. | Oprichter | - |
ImmuLogic Pharmaceutical Corp.
 ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | - |
Avaxia Biologics, Inc.
 Avaxia Biologics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company | Oprichter | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
| Bedrijven in privébezit | 9 |
|---|---|
ImmuLogic Pharmaceutical Corp.
ImmuLogic Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Avaxia Biologics, Inc.
Avaxia Biologics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Bryn Mawr College
 Bryn Mawr College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Maryland Medical System Corp.
University of Maryland Medical System Corp. Hospital/Nursing ManagementHealth Services Operates hospital | Health Services |
Recovery Pharmaceuticals, Inc. | |
Tilos Therapeutics, Inc.
Tilos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops antibody therapeutics for cancer, fibrosis and autoimmune disease | Health Technology |
The Engine Accelerator, Inc.
The Engine Accelerator, Inc. Investment ManagersFinance Engine Ventures seeks investment opportunities in companies located in the United States. The firm targets companies operating across a broad range of sectors and industries. It provides financing for early stage transactions. | Finance |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company developing novel medicines that modulate metabolic pathways in immune cells to treat disease | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
